PARIS, Sept 18- French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering aimed at financing late-stage trials of its Texopi drug for the most common form of lung cancer, the company said on Thursday.» Read More
NEW YORK, Aug 6- Drugmakers' use of the tobacco plant as a fast and cheap way to produce novel biotechnology treatments is gaining global attention because of its role in an experimental Ebola therapy.
The drug, developed by Mapp Biopharmaceutical Inc, was used to treat two workers from the Samaritan's Purse group who were exposed to the disease in Liberia, according to a U.S. government health official. The official said the treatment was administered in Liberia.
LONDON, July 24- GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.
July 17- Medical device and drug maker Baxter International Inc reported higher-than-expected quarterly adjusted earnings, driven primarily by a surge in sales of the dialysis products it gained from its acquisition of Gambro AB last year.
PARIS, July 11- The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.
PARIS, June 25- Eighteen French biotech firms, several newly listed on the Paris stock market, head to New York on Wednesday and Thursday to convince U.S. investors to help fund the next stages of their research and development.
June 24- A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.
WASHINGTON, June 24- A GlaxoSmithKline Plc plant in Canada that makes the flu vaccine Flulaval has been cited by the U.S. Food and Drug Administration for failing to meet quality control standards.
June 18- U.S. drugmaker Pfizer, which failed last month in a $118 billion bid to buy AstraZeneca, said on Wednesday it had signed a deal with French biotech Cellectis to develop immunotherapy drugs in cancer. Under the new deal, Cellectis will receive an upfront payment of $80 million, as well as funding for research costs.
As AstraZeneca's shares slid following its rejection of Pfizer's new bid, the company's chairman said he was "reasonably confident" it was the right decision.
May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.
The escalating euro continues to harm business, the chief financial officer of Royal DSM told CNBC, a day after the single currency took a beating.
LONDON, April 24- AstraZeneca highlighted progress with new cancer drugs that may revive its fortunes as it posted a 17 percent fall in core earnings per share on Thursday, reflecting patent losses on profitable older medicines.
Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.
LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.
ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.
April 14- Merck& Co said the U.S. Food and Drug Administration on Monday approved its grass pollen allergy drug Grastek, becoming the second such immunotherapy treatment to be given the go-ahead in recent weeks.
Shagun Chadha shares her top pick among medical appliance companies and gives other sector names she likes as well.
LONDON, April 2- GlaxoSmithKline Plc has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit.
April 1- France's Stallergenes said on Tuesday it received the U.S. Food and Drug Administration's green light to sell its immunotherapy pill Oralair for treating grass allergies. Oralair was approved in the European Union in 2008 and is also sold in Canada, Australia and Russia for the treatment of grass pollen allergy.